




Official Journal of the European Paediatric Neurology Society



Original article

Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥ 1 to < 4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303



Alexis Arzimanoglou ^{a,*}, Jose Ferreira ^{b,c,d}, Andrew Satlin ^e, Omar Olhaye ^e, Dinesh Kumar ^f, Shobha Dhadda ^f, Francesco Bibbiani ^e

^a Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology, University Hospitals of Lyon (HCL), Member of the European Reference Network EpiCARE, Lyon's Neuroscience Research Center, 59 Bld. Pinel, 69700 Lyon, France

^b Department of Pediatrics, University of South Florida, School of Medicine, Tampa General Cir, Tampa, FL 33606, USA

^c Pediatric Neurology, St. Joseph's Children's Hospital, 3001 W Doctor Ave, K Jr. Bld, Tampa, FL 33609, USA

^d Pediatric Epilepsy and Neurology Specialists (PEINS), 10 S. Habana Ave, Suite 310, Tampa, FL 33609, USA

^e Formerly of Eisai Neurology Business Group, Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, NJ 07677, USA

^f Eisai Neurology Business Group, Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, NJ 07677, USA

ARTICLE INFO

Article history:

Received 7 November 2017

Received in revised form

4 September 2018

Accepted 23 September 2018

Keywords:

Antiepileptic drug

Behavior

Children

Epilepsy

Neurodevelopment

Rufinamide

ABSTRACT

Objective: Evaluate the long-term safety, tolerability, and behavioral effects of adjunctive rufinamide in pediatric patients (≥ 1 to < 4 years old) with inadequately controlled seizures associated with Lennox-Gastaut syndrome (LGS).

Methods: Study 303 (ClinicalTrials.gov identifier NCT01405053) was a multicenter, randomized, open-label, Phase III trial. Patients were randomized (2:1) to oral suspension rufinamide (≤ 45 mg/kg/day) or any other investigator-chosen antiepileptic drug (AED) for a 2-year treatment period. Primary safety/tolerability assessments included monitoring of treatment-emergent adverse events (TEAEs) and serious TEAEs. Behavioral effects were assessed via the Child Behavior Checklist (CBCL) using the Total Problems score and change from baseline in CBCL Total Problems score. CBCL subscores were also evaluated. **Results:** The Safety Analysis Set included 37 patients (rufinamide: $n = 25$; any other AED: $n = 12$). TEAE incidence was similar between the rufinamide (88.0%) and any-other-AED groups (83.3%); serious TEAE incidence was also similar between treatment groups

Abbreviations: AE, adverse event; AED, antiepileptic drug; CBCL, child behavior checklist; ECG, electrocardiogram; EEG, electroencephalogram; EXC, exclusion; INC, inclusion; LDS, language development survey; LGS, Lennox-Gastaut syndrome; max, maximum; min, minimum; PK, pharmacokinetic; QoLCE, quality of life in childhood epilepsy; SD, standard deviation; TEAE, treatment-emergent adverse event.

* Corresponding author.

E-mail addresses: aarzimanoglou@orange.fr (A. Arzimanoglou), jferreira@pensresearch.org (J. Ferreira), andrew.satlin@gmail.com (A. Satlin), omar.olhaye@gmail.com (O. Olhaye), dinesh_kumar@eisai.com (D. Kumar), shobha_dhadda@eisai.com (S. Dhadda), fbibbiani@yahoo.com (F. Bibbiani).

<https://doi.org/10.1016/j.ejpn.2018.09.010>

1090-3798/© 2018 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Als Angehöriger
 medizinischer Fachkreise
 können Sie dieses Material
 gerne bei uns anfordern.